Presenting Reunion Neuroscience

SOLABS is proud to present our client Reunion Neuroscience

Reunion Neuroscience is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for postpartum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.

Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity, for potential use in more chronic treatment paradigms and indications.

Earlier this year, Stéphan Côté, Head of Quality, chose to implement SOLABS QM10 as his #eqms to manage controlled documents and quality processes.

A sincere #thankyou to Meg Burnie, Stéphan Côté and Paul Oakley for making SOLABS your business partner and for all your dedication to making this implementation successful!